A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death.
Saved in:
| Title: | A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death. |
|---|---|
| Authors: | Ray A; The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. arghya_ray@dfci.harvard.edu., Du T; The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Wan X; The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Song Y; The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Pillai SC; The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Musa MA; The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Fang T; The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Moore J; ORIC Pharmaceuticals, Inc., South San Francisco, CA, USA., Blank B; ORIC Pharmaceuticals, Inc., South San Francisco, CA, USA., Du X; ORIC Pharmaceuticals, Inc., South San Francisco, CA, USA., Chen X; ORIC Pharmaceuticals, Inc., South San Francisco, CA, USA., Warne R; ORIC Pharmaceuticals, Inc., South San Francisco, CA, USA., Sutimantanapi D; ORIC Pharmaceuticals, Inc., South San Francisco, CA, USA., Lui F; ORIC Pharmaceuticals, Inc., South San Francisco, CA, USA., Zavorotinskaya T; ORIC Pharmaceuticals, Inc., South San Francisco, CA, USA., Colas C; ORIC Pharmaceuticals, Inc., South San Francisco, CA, USA., Friedman L; ORIC Pharmaceuticals, Inc., South San Francisco, CA, USA., Junttila MR; ORIC Pharmaceuticals, Inc., South San Francisco, CA, USA., Chauhan D; The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Dharminder_Chauhan@dfci.harvard.edu., Anderson KC; The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Kenneth_Anderson@dfci.harvard.edu. |
| Source: | Blood cancer journal [Blood Cancer J] 2024 Apr 09; Vol. 14 (1), pp. 58. Date of Electronic Publication: 2024 Apr 09. |
| Publication Type: | Letter; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2044-5385 |
|---|---|
| DOI: | 10.1038/s41408-024-01019-5 |
